Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects

References

• COVID-19 vaccine market dashboard. [accessed 2022 Feb 4]. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard
   Google Scholar
• Hopkins’ J COVID-19 Dashboard. [accessed 2022 Feb 4]. https://coronavirus.jhu.edu/map.html
   Google Scholar
• Niesen MJM, Anand P, Silvert E, Niesen MJM, Corchado-Garcia J, O’Horo JC, Virk A, Swift MD, Halamka J, Badley AD, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRxiv. 2021. 2021.07.01.21259833. doi:10.1101/2021.07.01.21259833.
   PubMedGoogle Scholar
• European Medicines Agency. COVID-19 Vaccines [accessed 2022 Mar 12]. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
   Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–5. doi:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, Davenport MP. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21:395–404. doi:10.1038/s41577-021-00550-x.
   PubMed Web of Science ®Google Scholar
• Capetti AF, Borgonovo F, Mileto D, Gagliardi G, Mariani C, Lupo A, Dedivitiis G, Meraviglia P, Pellicciotta M, Armiento L, et al. One-Year durability of anti-spike IgG to SARS-CoV-2: preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG. J Infect. 2021;83(2):237–79. Epub 2021 May 27. doi:10.1016/j.jinf.2021.05.023.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, Guo L, Li X, Li J, Wang J, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022;7:423–33. doi:10.1038/s41564-021-01051-2.
   PubMed Web of Science ®Google Scholar
• Amedeo FC, As C, Fabio B, Mileto D, Letizia O, Gianfranco D, Angelica L, Maria VC, Lara B, Giacomelli A, et al. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 vaccine. Clin Infect Dis. 2021:ciab214. doi:10.1093/cid/ciab214.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• LIAISON® SARS-CoV-2 S1/S2 IgG a quantitative assay with correlation to neutralizing antibodies [accessed 2021 Nov 9]. https://www.diasorin.com/sites/default/files/allegati_prodotti/liaisonr_sars-cov-2_s1s2_igg_m0870004366-d_lr.pdf
   Google Scholar
• Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines. 2021;9:910. Giavarina D, Carta M. Improvements and limits of anti SARS-CoV-2 antibodies assays by WHO (NIBSC 20/136) standardization Diagnosis, 2021. doi:10.3390/vaccines9080910.
   Web of Science ®Google Scholar
• Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, Papleux E, Vekemans M, Beukinga I, Blairon L. Six-Month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: a third dose is expected. J Infect. 2021;S0163-4453(–3):433. Epub ahead of print. doi:10.1016/j.jinf.2021.08.031.
   Google Scholar
• Giménez E, Alberola J, Torres I, Albert E, Alcaraz MJ, Botija P, Amat P, Remigia MJ, Beltrán MJ, Rodado C, et al. Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine. J Infect. 2021; S0163-4453(21)542–49 DOI: 10.1016/j.jinf.2021.10.026.
   Google Scholar
• Pegu A, O’-Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021:eabj4176. doi:10.1126/science.abj4176.
   Google Scholar
• Thomas SJ, Ed M Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;NEJMoa2110345. Epub ahead of print. doi:10.1056/NEJMoa2110345.
   PubMedGoogle Scholar
• Pan H, Wu Q, Zeng G Yang J, Jiang D, Deng X, Chu K, Zheng W, Zhu F, Yu H, Yin W Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. Lancet Infect Dis 2021;S1473-3099(21)681–82. doi: 10.1016/S1473-3099(21)00681-2
   Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, Rubin C. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021 Dec 9;385(24):e84. Epub 2021 Oct 6. doi:10.1056/NEJMoa2114583
   PubMed Web of Science ®Google Scholar
• Wu F, Liu M, Wang A. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med 2020;180(10):1356–62. doi: 10.1001/jamainternmed.2020.4616. Erratum in: JAMA Intern Med. 2020 Oct 1;180(10):1405.
   Google Scholar